|Bid||18.32 x N/A|
|Ask||18.62 x N/A|
|Day's range||17.18 - 18.54|
|52-week range||15.07 - 22.81|
|Beta (5Y monthly)||-0.06|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||16 June 2016|
|1y target est||N/A|
Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events:
Indivior PLC (LSE: INDV) today announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares is now available at www.sec.gov and under the "Investors" section of the Company's website (www.indivior.com). Trading in Indivior's ordinary shares on the NASDAQ Global Select Market is expected to commence at the open on June 12, 2023, subject to approval by the U.S. Securities & Exchange Commission (SEC) and NASDAQ. Indivior will retain its prem
Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.2 OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respirat
Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.
Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event:
Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc. ("Opiant"). The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl.
Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at www.indivior.com.
CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign In
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute th
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant’s closing share price of November 11, 2022, and 99% premium to Opiant’s 30-day volume-weighted average share price; total consideration, inclusive of p
Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) ("Opiant") today announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up to $8.00 per share in contingent value rights ("CVRs") that may become payable in the event that certain net revenue milestones are achieved during the relevant
Indivior ( LON:INDV ) Third Quarter 2022 Results Key Financial Results Revenue: US$232.0m (up 24% from 3Q 2021). Net...
Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com.